SNCA and synucleinopathy: In summary, we showed further evidence that a 7-day chronic CPA i.p. injection rat model generated increased α-synuclein expression and aggregation, which provides a convenient model to assay several neuroprotective drugs, including the bifunctional compound C8–6–I, without waiting several months to observe the presence of α-synucleinopathies normally seen in genetic mouse of models of PD (e.g., A53T mouse model).